Equibles does not estimate personal net worth.
Jack Anders is recorded as CFO at Revolution Medicines, Inc. (RVMD). The newest filing on record that lists Jack Anders as CFO at Revolution Medicines, Inc. (RVMD) is dated April 27, 2026. Revolution Medicines, Inc. reported in an 8-K filed September 1, 2022 that Jack Anders was appointed Chief Financial Officer, effective September 1, 2022. The proxy statement of Revolution Medicines, Inc. reports total compensation of $3,588,111 for Jack Anders in fiscal 2025, including a base salary of $523,333. Disclosed compensation is on record for 5 fiscal years. Jack Anders has spoken on 15 earnings calls across 1 company, most recently for Revolution Medicines, Inc. on August 5, 2026. Revolution Medicines, Inc. is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at Revolution Medicines, Inc. includes Mark Goldsmith (CEO and Board Member), Margaret Horn (COO), Jeffrey Cislini (General Counsel) and 7 others.
“On September 1, 2022, the Board of Directors (the "Board") of Revolution Medicines, Inc. (the "Company") promoted Jack Anders, age 45, to serve as the Chief Financial Officer of the Company, effective immediately.”
“Our financial position remains exceptionally strong and continues to provide the flexibility needed to support the rapid advancement of our portfolio and our commercial preparations.”
“We ended the fourth quarter of 2025 with $2.03 billion in cash and investments. In 2025, we entered into our innovative and flexible strategic partnership with Royalty Pharma, which provided us access to up to $2 billion in committed capital under the terms of the agreement.”
“We ended the third quarter of 2025 with $1.93 billion in cash and investments.”
“Before turning to the second quarter financial results, I would like to review a few key highlights from our Royalty Pharma transaction.”
“We ended the first quarter of 2025 with $2.1 billion in cash and investments, which we project can fund planned operations into the second half of 2027 based on our current operating plan.”
Start not stated–present
Last confirmed April 27, 2026
Proxy statement
Start not stated–2022-04-26
Last confirmed by a filing; no departure on record
Biotechnology · Healthcare
CFO
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2025 | Revolution Medicines, Inc. (RVMD) | Chief Financial Officer | $523,333 | $3,588,111 |
| 2024 | Revolution Medicines, Inc. (RVMD) | Chief Financial Officer | $473,333 | $3,292,532 |
| 2023 | Revolution Medicines, Inc. (RVMD) | Chief Financial Officer | $438,384 | $3,047,529 |
| 2022 | Revolution Medicines, Inc. (RVMD) | Chief Financial Officer | $371,000 | $1,947,461 |
| 2021 | Revolution Medicines, Inc. (RVMD) | Chief Financial Officer | $311,333 | $1,509,614 |
